0
Your inquiries
Total:
Catalog of medicines India

Lenangio 10mg (Lenalidomide)

Lenangio 10mg (Lenalidomide)

Lenangio 10mg is used to treat this condition Mantle cell lymphoma:

Feature
Brand name:
Lenangio
Active substance:
Lenalidomide 10mg
Packaging:
10 Capsules
Product form:
Capsules
Strength:
10mg
Categories
In stock
Active substance: Lenalidomide
0 $
Options:
Amount:
To wishlist
Compared
Description

DESCRIPTION

Lenangio contains Lenalidomide as an active substance which belongs to thalidomide analogue. Lenangio contains some pharmacological activities like immuno modulatory, anti-neoplastic, & anti-angiogenesis. 
Lenangio is a prescription medicine; used under the supervision of medical oncologist. Lenangio is used by combining with dexamethasone.

INDICATION

The most common indications of Lenangio are; Multiple myeloma: Lenangio should be used in combination with dexamethasone. Myelodysplastic syndrome: Lenangio is used to treat this condition Mantle cell lymphoma: Lenangio is used for this condition, if patients are not responding to the Bortezomib treatment.

MECHANISM OF ACTION

Tumor cells asserted epidermal growth factor receptors on their cell surface, present in both active and cancer infected cells. These receptors complicated in advancement of cell growth and production. Some epidermal growth factor receptors have exciting mutations (changes) within non small cell lung cancer cells which are supposing to encourage cancer cell growth, restrict the apoptosis, which may raise angiogenic factors and develop metastasis process. Geffyenclose Gefitinib causes erratic prohibition of tyrosine kinase and provoke abnormality of EGFR, block the autophosphorylation of tyrosine debris similar with receptor, via inhibition of following signaling and blockade EGFR dependent multiplication.

DOSAGE MANAGEMENT

DOSAGE MANAGEMENT

The usual prescribed dose of Lynide  in myelodysplastic syndromes is 10mg should be given as once a day. For renal damaged patients; In Patients with CrCl >60ml/min should not require dosage adjustment of Lynide  . In Patients with CrCl 30 to 60ml/min, 5mg of Lynide  should be given orally as once a day. In Patient with CrCl < 30ml/min, 2.5mg of Lynide  should be administered orally as a once a day. Dosage variation;

THROMBOCYTOPENIA

Drops to <50000/mcL, therapy should be interrupted. Back to > or equal to 50000/mcL, continue the Lynide  of 5mg/day.

NEUTROPENIA

Drops to <500/mcL, therapy should be postponed. Back to > or equal to 500/mcL, treatment should be continue to 5mg/day.

MULTIPLE MYELOMA

In this condition, Lynide  is concomitant with dexamethasone. The usual dose of Lynide  is 25mg should be administered as once daily on day 1 to 21. The dose of dexamethasone; 40mg of dexamethasone should be followed on day 1 to 4, 9 to 12 & 17 to 20 of each 28 day cycles. Patient with >75 years, 20mg of dexamethasone should be recommended on day 1, 8, 15, & 22.

MANTLE CELL LYMPHOMA

The advised dose of Lynide  for this condition is 25mg should be administered orally as once daily. For renal damaged patients; Patient with CrCl 30 to 60ml/min, 10mg of Lynide  should be administered as once daily. Patient with CrCl < 30ml/min, 15mg of Lynide  should be used for q48hr. Pediatrics; The potency & effectiveness of Lenalidomide has not been evaluated in pediatric patients with age of <18 years.

SIDE EFFECTS

SIDE EFFECTS

Second primary malignancies Liver toxicity Hypersensitivity reactions Tumor lysis syndrome Tumor flare reactions Thyroid disorders Fetal toxicity Hematological toxicity Elevation of mortality rate

COMMON SIDE EFFECTS

Fatigue Asthenia Pyrexia Diabetes mellitus Rash Insomnia Depression Deep vein thrombosis Myocardial infraction Renal failure Squamous cell carcinoma Basal cell carcinoma Pain Diarrhea Dyspepsia Bone pain Neck pain Muscle weakness, pain Respiratory infections UTI Influenza Sepsis Headache Anemia Loss of appetite Hypokalemia Hyperglycemia Hypocalcaemia Dehydration Gout

DRUG INTERACTION

Lenangio + digoxin, causes increased concentration of digoxin causes increased risk of adverse effects related to digoxin. Lenangio + Erythropoietic agents, leads to produced increased risk of thrombosis. Counsel the patients before starting this combination treatment. Lenangio + warfarin, causes increased exposure of bleeding disorders. Monitor the INR value & prothrombin time.

CONTRAINDICATION

Lenangio should be contraindicated to pregnancy period. Hypersensitivity reactions are produced due to patients are contraindicated to the Lenangio component.

WARNING

The most common life threatening condition like Embryo fetal damage Hypersensitivity reactions Venous & arterial thromboembolism Blood clotting effects Hematological disorders For all these conditions, some supportive measures should be used and provide safety measures.

PREGNANCY & LACTATION

Pregnancy category X Lenangio causes fetal damage leads to death Breast feeding should not be allowed

STORAGE 

Lenangio capsules should be stored at 20°C to 25°C Protect the container from light Keep away from moisture & heat.

OVER DOSAGE

Over dosage of Lenangio leads to neutropenia & thrombocytopenia as most common adverse effects. Provide general supportive therapy. Monitor the blood cells counts frequently during the treatment.

MISSED DOSE

The missed dose of Lenangio should be avoided. If missed dose occurs, then patients should be consulting with medical oncologist Maintain the regular dosing schedule.

Feature
Brand name
Lenangio
Active substance
Lenalidomide 10mg
Packaging
10 Capsules
Product form
Capsules
Strength
10mg
Lenangio 10mg (Lenalidomide)
Add a comment
0

There are no comments yet

Payment
Delivery
We use cookies to make the site better for you! Note: We strongly encourage you to talk with your health care professional about your specific medical condition and treatments.